2026 Verified Benchmark & Execution Guide
How to Prevent Muscle Loss & 'Ozempic Face' on Semaglutide & Tirzepatide: The Leucine-Threshold Protocol
Why 39% of unmanaged GLP-1 weight loss comes from lean muscle (STEP-1 Trial) and how 1.6g/kg protein dosing stops sarcopenia.
Need this exact packet customized for your state/case in 10 seconds?
Launch GLP1Keep Generator ($9.90) →
1. Quantitative Benchmarks & Statutory / Clinical Standards
| Parameter / Rule | Standard / Threshold | Actionable Savings / Protection |
|---|---|---|
| STEP-1 Trial Baseline | 13.9 lbs Lean Mass Lost out of 33.7 lbs Total Loss | 39% of unmanaged weight loss was muscle & organ tissue |
| Leucine mTOR Trigger | 3.0g–3.5g L-Leucine Per Meal (≈35g–40g Complete Protein) | Overcomes caloric-deficit anabolic resistance in skeletal muscle |
| Collagen + Creatine Stack | 15g Verisol/Peptiplus Collagen + 5g Creatine Monohydrate | Preserves dermal extracellular matrix & intracellular muscle hydration |
2. Step-by-Step Execution Protocol
When appetite drops by 60% on semaglutide or tirzepatide, patients naturally eat small portions of carbohydrates and fats while falling below 45g of protein per day. At that intake, the body catabolizes skeletal muscle and facial dermal collagen for amino acids. Hitting 1.6g/kg of goal body weight in protein across 3 leucine-rich micro-meals reduces lean-mass loss from 39% to under 8%.
Instant Digital Delivery · Zero Wait
Generate Your Complete GLP1Keep Packet Now ($9.90 Starter / $19.00 VIP)